Procept BioRobotics Believes Aquablation Could Dominate BPH Treatment…If It Gets Coverage
Executive Summary
Results of the WATER II trial confirm that Aquablation is a safe and effective treatment of benign prostate hyperplasia for large prostates, and manufacturer Procept BioRobotics is confident the procedure will eventually displace all other prostate resection techniques because it is easy for surgeons to learn.
You may also be interested in...
CMS Weighs Merits Of New Pass-Through Payments For Aquabeam System, Eluvia Stents In OPPS Proposal
The US Medicare agency has been scrutinizing two new devices that have generated some buzz within the industry for pass-through payment status under its proposed 2020 Outpatient Prospective Payment System (OPPS) rules. The devices are Procept BioRobotic’s AquaBeam System for removal of prostate tissue in men with urinary tract symptoms, and Boston Scientific’s Eluvia drug-eluting stent for treatment of peripheral artery disease.
Procept's Aquablation BPH Therapy Gets Boost From UK NICE Guidance
The UK's NICE issued a recommendation approving Procept's AquaBeam Aquablation therapy as an alternative to surgical treatments for benign prostate hyperplasia just as a Medciare new technology add-on payment takes effect for Aquablation in the US.
Three Devices Gain Medicare Add-Ons, Including Boston Sci's New TAVR Protector
The US Medicare agency granted inpatient new-technology add-on payments for Boston Scientific's newly acquired cerebral protection system for TAVR, Respicardia's neurostimulator for sleep apnea and Procept BioRobotics' novel resection system for benign prostatic hyperplasia. The highly selective bonus payments typically help drive adoption for the chosen new technologies.